Utilization of galectin-3 in case management across the spectrum of heart failure

Reviews in Cardiovascular Medicine

Volumn 15, Issue 3, 2014, Pages 197-207

  McCullough, Peter ^a,b   De Boer, Rudolph A ^c   Edelmann, Frank ^d   Lewis, Connie M ^e   Maisel, Alan S ^f  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b The Heart Hospital   (United States)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d UNIVERSITY OF GÖTTINGEN   (Germany)

^e VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^f VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

Biomarker; Chronic kidney disease; Galectin 3; Heart failure; Hospitalization; Medical management; Mortality

Indexed keywords

CARVEDILOL; FUROSEMIDE; GALECTIN 3; HYDRALAZINE; INSULIN GLARGINE; ISOSORBIDE DINITRATE; LISINOPRIL; SHORT ACTING INSULIN; SPIRONOLACTONE;

ACUTE CORONARY SYNDROME; DRUG UTILIZATION; HEART FAILURE; HEART MUSCLE FIBROSIS; HUMAN; MOLECULAR PATHOLOGY; NONSYSTOLIC HEART FAILURE; PREDICTIVE VALUE; REVIEW;

EID: 84908241795     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: 10.3909/ricm0726     Document Type: Review

References (36)

1. Raghava, V, Ramachandran, V. Epidemiology of heart failure. In: Mann DL, ed. Heart Failure: A Companion to Braunwalds Heart Disease. 2nd ed. Saint Louis, MO: Elsevier Saunders; 2011.
2. McMurray JJV. What is heart failure. In: Abraham WT, Krum H, eds. Heart Failure: A Practical Approach to Treatment. New York, NY: McGraw Hill; 2007.
3. Vasquez C, Benamer N, Morley GE. The cardiac fibroblast: functional and electrophysiological considerations in healthy and diseased heart. J Cardiovasc Pharmacol. 2011;57:380-388.
4. McCullough PA, Philbin EF, Spertus JA, et al; Resource Utilization Among Congestive Heart Failure (REACH) Study. Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. J Am Coll Cardiol. 2002;39:60-69.
5. Soman P, Lahiri A, Mieres JH, et al. Etiology and pathophysiology of new-onset heart failure: evaluation by myocardial perfusion imaging. J Nucl Cardiol. 2009;16:82-91.
6. van den Borne SW, Diez J, Blankesteijn WM, et al. Myocardial remodeling after infarction: the role of myofibroblasts. Nat Rev Cardiol. 2010;7:30-37.
7. Felker GM, Shaw LK, OConner CM. A standardized definition of ischemic cardiomyopathy for use in clinical research. J Am Coll Cardiol. 2002;39:210-218.
8. Michels VV, Moll PP, Miller FA, et al. The frequency of familial dilated cardiomyopathy in a series of patients with idiopathic dilated cardiomyopathy. N Engl J Med. 1992;326:77-82.
9. Hutchinson KR, Stewart JA Jr, Lucchesi PA. Extracellular matrix remodeling during the progression of volume overload-induced heart failure. J Mol Cell Cardiol. 2010;48:564-569.
10. Cruz DN, Schmidt-Ott KM, Vescovo G, et al. Pathophysiology of cardiorenal syndrome type 2 in stable chronic heart failure: workgroup statements from the eleventh consensus conference of the Acute Dialysis Quality Initiative (ADQI). Contrib Nephrol. 2013;182:117-136.
11. Henderson NC, Mackinnon AC, Farnworth SL, et al. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol. 2008;172:288-298.
12. McCullough PA, Olobatoke A, Vanhecke TE. Galectin-3: a novel blood test for the evaluation and management of patients with heart failure. Rev Cardiovasc Med. 2011;12:200-210.
13. Creemers EE, Pinto YM. Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart. Cardiovasc Res. 2011;89:265-272.
14. Cooper DN. Galectinomics: finding themes in complexity. Biochim Biophys Acta. 2002;1572:209-231.
15. Dumic J, Dabelic S, Flogel M. Galectin-3: an openended story. Biochim Biophys Acta. 2006;1760:616-635.
16. Krzes̈lak A, Lipińska A. Galectin-3 as a multifunctional protein. Cell Mol Biol Lett. 2004;9:305-328.
17. Raimond J, Zimonjic DB, Mignon C, et al. Mapping of the galectin-3 gene (LGALS3) to human chromosome 14 at region 14q21-22. Mamm Genome. 1997;8:706-707.
18. Henderson NC, Sethi T. The regulation of inflammation by galectin-3. Immunol Rev. 2009;230:160-171.
19. Liu YH, DAmbrosio M, Liao TD, et al. N-Acetyl-serylaspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin. Am J Physiol Heart Circ Physiol. 2009;296:H404-H412.
20. Sharma UC, Pokharel S, van Brakel TJ, et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation. 2004;110:3121-3128.
21. Dang Z, MacKinnon A, Marson LP, Sethi T. Tubular atrophy and interstitial fibrosis after renal transplantation is dependent on galectin-3. Transplantation. 2012;93:477-484.
22. McCullough PA, Kellum JA, Haase M, et al. Pathophysiology of the cardiorenal syndromes: executive summary from the eleventh consensus conference of the Acute Dialysis Quality Initiative (ADQI). Contrib Nephrol. 2013;182:82-98.
23. de Boer RA, van Veldhuisen DJ, Gansevoort RT, et al. The fibrosis marker galectin-3 and outcome in the general population. J Intern Med. 2012;272:55-64.
24. van Kimmenade RR, Januzzi JL Jr, Ellinor PT, et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol. 2006;48:1217-1224.
25. Ho JE, Liu C, Lyass A, et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol. 2012;60:1249-1256.
26. Grandin EW, Jarolim P, Murphy SA, et al. Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22. Clin Chem. 2012;58:267-273.
27. Lin YH, Lin LY, Wu YW, et al. The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients. Clin Chim Acta. 2009;409:96-99.
28. de Boer RA, Lok DJ, Jaarsma T, et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med. 2011;43:60-68.
29. van der Velde AR, Gullestad L, Ueland T, et al. Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH. Circ Heart Fail. 2013;6:219-226.
30. Wu AH, Smith A. Biological variation of the natriuretic peptides and their role in monitoring patients with heart failure. Eur J Heart Fail. 2004;6:355-358.
31. Chinnaiyan KM, Alexander D, Maddens M, Mc-Cullough PA. Curriculum in cardiology: integrated diagnosis and management of diastolic heart failure. Am Heart J. 2007;153:189-200.
32. Chinnaiyan KM, Alexander D, McCullough PA. Role of angiotensin ii in the evolution of diastolic heart failure. J Clin Hypertens (Greenwich). 2005;7: 740-747.
33. Zile MR, DeSantis SM, Baicu CF, et al. Plasma galectin-3 levels in patients with structural and clinical manifestations of hypertensive heart disease: relationship to determinants of matrix composition. Circulation. 2010;122(suppl):A12433.
34. Shah RV, Chen-Tournoux AA, Picard MH, et al. Galectin-3, cardiac structure and function, and longterm mortality in patients with acutely decompensated heart failure. Eur J Heart Fail. 2010;12:826-832.
35. OSeaghdha CM, Hwang SJ, Ho JE, et al. Elevated galectin-3 precedes the development of CKD. J Am Soc Nephrol. 2013;24:1470-1477.
36. Shenkman HJ, Pampati V, Khandelwal AK, et al. Congestive heart failure and QRS duration: establishing prognosis study. Chest. 2002;122:528-534.